BioVie (NASDAQ:BIVI) reported topline Phase 2 ADDRESS-LC trial results for bezisterim in Long COVID, showing statistically significant improvements in pre-specified subgroups with higher baseline fatigue, cognitive impairment, and post-exertional malaise.
Arrowhead Pharmaceuticals (NASDAQ:ARWR) reported interim topline data from a Phase 1/2a clinical trial of ARO-DIMER-PA, an investigational RNA interference therapy designed to silence PCSK9 and APOC3 genes for patients with mixed hyperlipidemia.
Eli Lilly (NYSE:LLY) will present new clinical trial data on retatrutide, Foundayo (orforglipron), and eloraTZP at the European Association for the Study of Diabetes 2026 meeting in Milan from September 28 to October 2.
Strawberry Fields REIT (NYSE:STRW) completed the acquisition of a healthcare campus in Marshall, Missouri, adding a 60-bed hospital, a 99-bed skilled nursing facility, and a medical office building to its portfolio.
Summit Therapeutics (NASDAQ:SMMT) reported updated overall survival results from the global Phase III HARMONi clinical trial showing ivonescimab plus chemotherapy continued to demonstrate survival results in patients with EGFR-mutated advanced non-small cell lung cancer.
Allarity Therapeutics (NASDAQ:ALLR) received a Japanese patent for its stenoparib-specific DRP companion diagnostic, covering methods to identify patients likely to benefit from stenoparib treatment.
Abbott (NYSE:ABT) agreed to pay $385 million on September 14, 2026, to resolve government and civil claims connected to its 2022 powdered infant formula recall.
Johnson & Johnson (NYSE:JNJ) is reportedly in discussions to sell its DePuy Synthes orthopedics business to Apollo Global Management for approximately $20 billion.
Biofrontera (NASDAQ:BFRI) received U.S. FDA approval of a supplemental New Drug Application for its Ameluz 10% topical gel and BF-RhodoLED lamp to treat adult patients with superficial basal cell carcinoma.
Amgen (NASDAQ:AMGN) received U.S. FDA approval to update the prescribing information for IMDELLTRA, reducing the initial monitoring time to 6–8 hours.
Pasithea Therapeutics (NASDAQ:KTTA) announced that it will present initial clinical data from Part A of its ongoing Phase 1/1b trial evaluating PAS-004 in adults with neurofibromatosis type 1 (NF1).
Corbus Pharmaceuticals (NASDAQ:CRBP) reported Phase 1b data showing a 5% mean weight loss with CRB-913 after 12 weeks.
